096760.KS
JW Holdings Corporation
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 4,180.00
+0.00%Year over year
Reported trailing growth
- Revenue
- +10.1%
- EBITDA
- -50.0%
- EBIT
- +18.4%
- EPS
- +150.0%
- Free cash flow
- +312.2%
- Operating cash flow
- +185.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.9%
- EBITDA
- +13.2%
- EBIT
- +13.9%
- Net income
- +38.2%
- EPS
- +40.0%
- Free cash flow
- +57.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026